Cuộc họp báo cáo kết quả kinh doanh Q2 2026 của Humacyte (HUMA): sBLA lọc máu dự kiến vào tháng 11
Cuộc họp báo cáo kết quả kinh doanh quý 2 năm 2026 của Humacyte đã ghi nhận doanh thu 0,4 triệu USD, dữ liệu lọc máu tích cực từ V012 và mục tiêu nộp hồ sơ sBLA cho ATEV vào tháng 11.
Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.